Huma

Huma (formerly known as Medopad) enables patients to capture health data through a range of non-invasive devices and transmit them to doctors and other health professionals through APIs. Its digital ‘hospital at home’ and decentralised clinical trial platform uses real-time health data from smartphones to help patients, clinicians, researchers, and healthcare systems. alike.

Within Healthcare, Huma uses data analytics, AI-powered apps and IoT to create digital biomarkers - real-time insights on a patient's individual health and wellbeing, enabling doctors to intervene as early as possible when needed. The ‘hospital at home’ system was co-created with clinicians and has been independently shown to almost double clinical capacity, reduce hospital readmissions by over a third and has patient adherence levels of over 90%.

Within Life Sciences, Huma's virtual solutions also support the remote collection of patient-generated data through phases of clinical development, post-approval research, real-world monitoring, and development of digital biomarkers, and companion products. Its platform provides remote patient data capture including e-consent, ePRO collection, biometric capture, data ingestion from wearables, use of digital endpoints, and telemedicine visits.

Huma works with businesses across the healthcare industry, including healthcare providers, pharmaceutical companies, insurers and technology companies, including Apple, AstraZeneca, Bayer and Janssen and academic institutions such as Stanford Medicine, the Johns Hopkins Bloomberg School of Public Health and the University of Cambridge.

The company is currently working on a range of solutions or tests for various medical issues, including Parkinson's and Alzheimers.

In October 2018, Huma announced it was working with China technology giant Tencent on an AI project to help track Parkinson's patients movements using mobile phones. That same year, Huma also formed a partnership with insurer Ping An, and with the Chinese divisions of Johnson & Johnson and GSK.

In November 2019 Huma raised $25m in Series B funding, led by Bayer, which plans to partner with Huma to build digital biomarkers and therapeutics for the heart. The round has led to a post-money valuation of $200m-300m.

In April 2020 the company rebranded to Huma, and acquired healthtech startups Biobeats and Tarilian Laser Technologies (TLT). The acquisitions enable Huma to continue buildings on their remote patient monitoring, whilst expanding into therapeutics and cardiovascular biomarkers.

In May 2021 Huma raised $130m for their two-part proposition focussed on patient monitoring and treatment from home and 'decentralised clinical trials'. A further commitment of $70 million that can be exercised at a later date has also been agreed as part of the Series C funding round and takes the total financing raised to more than $200 million. The new investment will be used to expand Huma’s digital platform in the US, Asia and the Middle East